Diseño in silico, síntesis y efecto en la actividad Ca2+ -ATPasa de CtpF de los compuestos derivados del núcleo pirrolo[1,2- a]quinoxalinas con potencial antimicobacteriano

dc.contributor.advisorSalazar Pulido, Luz Mary
dc.contributor.advisorOchoa Puentes, Cristian
dc.contributor.authorRodriguez Afanador, Michael Daniela
dc.contributor.researchgroupBioquímica y Biología Molecular de las Micobacteriasspa
dc.contributor.researchgroupSíntesis Orgánica Sosteniblespa
dc.date.accessioned2022-06-08T17:11:08Z
dc.date.available2022-06-08T17:11:08Z
dc.date.issued2021
dc.descriptionilustraciones, graficas, tablasspa
dc.description.abstractLa Ca2+-ATPasa tipo P de CtpF de Mycobacterium tuberculosis (Mtb), es un transportador de membrana fundamental en la homeóstasis iónica y la viabilidad celular de la micobacteria; posee un sitio de unión cuya interacción con compuestos inhiben la función enzimática y la actividad micobacteriana. Teniendo en cuenta lo anterior, se postularon y estudiaron mediante estrategias in silico, compuestos con el núcleo pirrolo[1,2- a]quinoxalínico sustituido en la posición C-4 como posibles inhibidores de CtpF, ya que han mostrado en estudios anteriores un amplio perfil farmacológico, contra bacterias, virus, y con actividad antitumoral, sin embargo, su potencial antituberculoso no ha sido explorado. Consecuentemente, el objetivo de este trabajo fue diseñar, sintetizar y evaluar el efecto en la actividad Ca2+ -ATPasa de CtpF de algunos compuestos derivados del núcleo pirrolo[1,2-a]quinoxalínico con potencial antimicobacteriano. Se Identificaron los compuestos 4-(3,4-metilenedioxifenil)pirrolo[1,2-a]quinoxalina 4b y 4-(2-clorofenil)pirrolo[1,2-a]quinoxalina 4c como posibles inhibidores de CtpF por medio de un cribado virtual y acoplamiento molecular. La síntesis de ambas moléculas se realizó con el uso de Solventes de punto eutéctico bajo (DES) como disolventes y catalizadores, obteniendo tiempos de reacción cortos, alta pureza en los productos y procesos amigables con el ambiente, lo cual es una mejora en la síntesis de estos compuestos. Se estudió la inhibición de ambas moléculas sobre la actividad Ca2+ -ATPasa de CtpF, se obtuvo un 30.51% para 4c y 18.17% para 4b. El compuesto 4b presentó una Concentración Mínima Inhibitoria (CMI) interesante de 25 µg/mL, lo cual lo convierte en un candidato promisorio como posible antituberculoso. Ninguna de las moléculas presentó toxicidad sobre células eucariotas; por lo tanto, su optimización puede contribuir al desarrollo de nuevos compuestos antimicobacterianos. (Texto tomado de la fuente)spa
dc.description.abstractThe P-type Ca2+-ATPase of CtpF from Mycobacterium tuberculosis (Mtb), a membrane transporter essential for ionic homeostasis and cell viability of mycobacteria, possesses a binding site whose interaction with compounds inhibits enzymatic function and mycobacterial activity. Considering the above, compounds with the pyrrolo[1,2- a]quinoxalinic core substituted at the C-4 position were postulated and studied by in silico strategies as possible CtpF inhibitors, since they have shown in previous studies a broad pharmacological profile, against bacteria, viruses, and with antitumor activity, however, their antituberculosis potential has not been explored. Consequently, the aim of this work was to design, synthesize and evaluate the effect on the Ca2+-ATPase activity of CtpF of some compounds derived from the pyrrolo[1,2- a]quinoxaline cores with antimycobacterial potential. Compounds 4-(3,4- methylenedioxyphenyl)pyrrolo[1,2-a]quinoxalin 4b and 4-(2-chlorophenyl)pyrrolo[1,2- a]quinoxalin 4c were identified as potential CtpF inhibitors by virtual screening and molecular docking. The synthesis of both molecules was performed with the use of Low Eutectic Point Solvents (DES) as solvents and catalysts, obtaining short reaction times, high purity in the products and environmentally friendly processes, which is an improvement in the synthesis of these compounds. The inhibition of both molecules on the Ca2+ -ATPase activity of CtpF was studied, 30.51% was obtained for 4c and 18.17% for 4b. Compound 4b presented an interesting Minimum Inhibitory Concentration (MIC) of 25 µg/mL, which makes it a promising candidate as a possible antituberculous. None of the molecules showed toxicity on eukaryotic cells; therefore, their optimization may contribute to the development of new antimycobacterial compounds.eng
dc.description.degreelevelMaestríaspa
dc.description.degreenameMagíster en Bioquímicaspa
dc.format.extentxvi, 78 paginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/81534
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.departmentDepartamento de Químicaspa
dc.publisher.facultyFacultad de Cienciasspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Ciencias - Maestría en Ciencias - Bioquímicaspa
dc.relation.referencesAbbott, A. P., Boothby, D., Capper, G., Davies, D. L., & Rasheed, R. K. (2004). Deep Eutectic Solvents formed between choline chloride and carboxylic acids: Versatile alternatives to ionic liquids. Journal of the American Chemical Society, 126(29), 9142– 9147. https://doi.org/10.1021/ja048266jspa
dc.relation.referencesAhmad, S., & Mokaddas, E. (2009). Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Respiratory medicine, 103(12), 1777– 90spa
dc.relation.referencesAlós, J.-I. (2015). Resistencia bacteriana a los antibióticos: una crisis global. Enfermedades Infecciosas y Microbiología Clínica, 33(10), 692–699. https://doi.org/10.1016/j.eimc.2014.10.004spa
dc.relation.referencesCaminero, J. A. (2006). Treatment of multidrug-resistant tuberculosis: evidence and controversies. The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union against Tuberculosis and Lung Disease, 10(8), 829–837.spa
dc.relation.referencesCampillo, N. E., Naranjo, P. G., & Paez, J. A. (2011). Presente y Futuro en el Descubrimiento de Fármacos para la Enfermedad de Chagas. Instituto de Química Médica. CSIC. http://www.anales.ranf.com/ojs/2012/01/08.htmspa
dc.relation.referencesChaudhary, K. kumar, & Mishra, N. (2016). A Review on Molecular Docking: Novel Tool for Drug Discovery Design of Novel small molecule mimics binding to quorum sensors in Ralstonia Solanacearum View project synthesis of nanocomposites for drug delivery View project Central Bringing Excellence in O. A Review on Molecular Docking: Novel Tool for Drug Discovery. JSM Chem, 4(3), 1029.spa
dc.relation.referencesChingaté L, S. M. (2012). Análogos de péptidos antimicrobianos con potencial actividad como compuestos antituberculosos. Universidad Nacional de Colombia.spa
dc.relation.referencesCires Pujol, M. (2002). La resistencia a los antimicrobianos, un problema mundial. Revista Cubana de Medicina General Integral, 18(2), 165–168. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252002000200012&lng=es&nrm=iso&tlng=enspa
dc.relation.referencesColl, P. (2003). Fármacos con actividad frente a Mycobacterium tuberculosis. Tuberculosis, 299–307.spa
dc.relation.referencesCurvo, L., Teixeira, L., & Caseiro, F. (2005). Tuberculosis of the chest. European Journal of Radiology, 55(2), 158–172. https://doi.org/10.1016/j.ejrad.2005.04.014spa
dc.relation.referencesDe La Fuente-Salcido, N. M., Villarreal-Prieto, M., Ángel, M., León, D., Patricia, A., Pérez, G., Norma, D., & De La Fuente-Salcido, M. (2015). Evaluation of the activity of antimicrobial agents against the challenge of bacterial resistance. Revista Mexicana de Ciencias Farmacéuticas, 2(46), 1–16. http://www.scielo.org.mx/pdf/rmcf/v46n2/1870-0195-rmcf-46-02-00007.pdfspa
dc.relation.referencesDesplat, V., Moreau, S., Gay, A., Fabre, S. B., Thiolat, D., Massip, S., Macky, G., Godde, F., Mossalayi, D., Jarry, C., & Guillon, J. (2010). Synthesis and evaluation of the antiproliferative activity of novel pyrrolo[1,2-a]quinoxaline derivatives, potential inhibitors of Akt kinase. Part II. Journal of Enzyme Inhibition and Medicinal Chemistry, 25(2), 204–215. https://doi.org/10.3109/14756360903169881spa
dc.relation.referencesDover, L. G., Bhatt, A., Bhowruth, V., Willcox, B. E., & Besra, G. S. (2008). New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections. Expert Review of Vaccines, 7(4), 481–497. https://doi.org/10.1586/14760584.7.4.481spa
dc.relation.referencesDupont, C., Viljoen, A., Thomas, S., & Roquet-banères, F. (2017). Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus and is effective in infected zebrafish Downloaded from http://aac.asm.org/ on August 17 , 2017 by FUDAN UNIVERSITY Downloaded from http://aac.asm.org/ on August 17 , 2017 by FUDAN UNIVERSITY. American Society for Microbiology, August. https://doi.org/10.1128/AAC.01225-17spa
dc.relation.referencesEl-Elimat, T., Raja, H. A., Figueroa, M., Swanson, S. M., Falkinham, J. O., Lucas, D. M., Grever, M. R., Wani, M. C., Pearce, C. J., & Oberlies, N. H. (2015). Sorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from Scytalidium album. Journal of Antibiotics, 68(3), 191–196. https://doi.org/10.1038/ja.2014.125spa
dc.relation.referencesFabian, L. E. (2015). Diseño y síntesis de análogos quinoxalínicos con potencial actividad quimioterápica [Universidad de Buenos Aires]. http://repositoriouba.sisbi.uba.ar/gsdl/collect/posgrauba/index/assoc/HWA_1139.dir/1139.PDFspa
dc.relation.referencesFilimonov, D., Lagunin, A., Gloriozova, A., Rudik, D., Druzhilovskii, P., Pogodin, V., & Poroikov, V. (2014). Prediction of the biological activity spectra of organic compounds using the PASS online web resource (No. 50; p. way2drug.com). Chemistry of Heterocyclic Compound. http://www.way2drug.com/passonline/definition.phpspa
dc.relation.referencesGorocica, P., Jimenez, M. del C., Garfias, Y., Sada, I., & Lascurian, R. (2005). Componentes glicosilados de la envoltura de Mycobacterium tuberculosis que intervienen en la patogénes de la tuberculosis. Revista Del Instituto Nacional de Enfermedades Respiratorias, 18(2), 142–153spa
dc.relation.referencesGuillom, J., Dallemagnea, P., Pfeifferb, B., Renard, P., Manechez, D., Kervrand, A., & Raulv, S. (1998). Synthesis of new pyrrolo[1,2-a]quinoxalines: potential non-peptide glucagon receptor antagonists Jean Guillom, Patrick Dallemagnea, Bruno Pfeifferb, Pierre Renard b, Dominique Manechez~, Alain Kervrand, Sylvain Raulv,*. 33, 293–308.spa
dc.relation.referencesGuillon, J., Cohen, A., Gueddouda, N. M., Das, R. N., Moreau, S., Ronga, L., Savrimoutou, S., Basmaciyan, L., Monnier, A., Monget, M., Rubio, S., Garnerin, T., Azas, N., Mergny, J. L., Mullié, C., & Sonnet, P. (2017). Design, synthesis and antimalarial activity of novel bis{N-[(pyrrolo[1,2-a]quinoxalin-4-yl)benzyl]-3-aminopropyl}amine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 32(1), 547–563. https://doi.org/10.1080/14756366.2016.1268608spa
dc.relation.referencesGuillon, J., Forfar, I., Mamani-Matsuda, M., Desplat, V., Saliège, M., Thiolat, D., Massip, S., Tabourier, A., Léger, J. M., Dufaure, B., Haumont, G., Jarry, C., & Mossalayi, D. (2007). Synthesis, analytical behaviour and biological evaluation of new 4-substituted pyrrolo[1,2-a]quinoxalines as antileishmanial agents. Bioorganic and Medicinal Chemistry, 15(1), 194–210. https://doi.org/10.1016/j.bmc.2006.09.068spa
dc.relation.referencesGuillon, J., Le Borgne, M., Rimbault, C., Moreau, S., Savrimoutou, S., Pinaud, N., Baratin, S., Marchivie, M., Roche, S., Bollacke, A., Pecci, A., Alvarez, L., Desplat, V., & Jose, J. (2013). Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a] quinoxaline derivatives as inhibitors of the human protein kinase CK2. European Journal of Medicinal Chemistry, 65, 205–222. https://doi.org/10.1016/j.ejmech.2013.04.051spa
dc.relation.referencesHanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeersch, T., Zurek, E., & Hutchison, G. R. (2012). Avogadro: un editor químico semantico avanzado, plataforma de visualización y analisis (1.2.0). Journal of Cheminformatics. http://avogadro.cc/spa
dc.relation.referencesHern, C. R. (2019). Determinación de características funcionales de CtpF, una Ca 2+ - ATPasa tipo P de Mycobacterium tuberculosis [Universidad Nacional de Colombia]. http://bdigital.unal.edu.co/72633/1/1026577431.2019.pdfspa
dc.relation.referencesHorsburgh, R., Barry, C., & Lange, C. (2015). Treatment of tuberculosis. The New Engl and Journal of Medicine, 373(11), 2149–2160. https://doi.org/10.1056/NEJMra1413919spa
dc.relation.referencesJager, V., Dawson, R., Niekerk, C., Vanker, N., Merwe, L., Choi, J., & Diacon, A. (2020). Telacebec (Q203), a New Antituberculosis Agent To. New England Journal of Medicine, 382(13), 1278–1280. https://doi.org/10.1056/nejmc2001899spa
dc.relation.referencesJiménez, M. A., García, R. S., Sarmiento, A. M., Guidet, L. G., Gálvez, J., & García-Domenech, R.(2016). Application of molecular topology for predicting the leishmanicidal activity of a group of compounds derived from pyrrolo [1,2-α] quinoxaline. Anales de La Real Academia Nacional de Farmacia, 82(3), 317–323.spa
dc.relation.referencesKandasamy, S., Hassan, S., Gopalaswamy, R., & Narayanan, S. (2014). Homology modelling, docking, pharmacophore and site directed mutagenesis analysis to identify the critical amino acid residue of PknI from Mycobacterium tuberculosis. Journal of Molecular Graphics and Modelling, 52, 11–19. https://doi.org/10.1016/j.jmgm.2014.05.011spa
dc.relation.referencesKant S, Maurya AK, Kushwaha RA, Nag VL, Prasad R. Multi-drug resistant tuberculosis: an iatrogenic problem. Biosci Trends. 2010 Apr;4(2):48-55. PMID: 20448341.spa
dc.relation.referencesKapetanovic, I. M. (2008). Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach. Chemico-Biological Interactions, 171, 165–176. https://doi.org/10.1016/j.cbi.2006.12.006spa
dc.relation.referencesKhalifa, R. A., Nasser, M. S., Gomaa, A. A., Osman, N. M., & Salem, H. M. (2013). Resazurin Microtiter Assay Plate method for detection of susceptibility of multidrug resistant Mycobacterium tuberculosis to second-line anti-tuberculous drugs. Egyptian Journal of Chest Diseases and Tuberculosis, 62(2), 241–247. https://doi.org/10.1016/j.ejcdt.2013.05.008spa
dc.relation.referencesKlenc, J., Raux, E., Barnes, S., Sullivan, S., Duszynska, B., Bojarski, A. J., & Strekowski, L. (2009). Synthesis of 4-Substituted 2- ( 4-Methylpiperazino ) pyrimidines and Quinazoline Analogs as Serotonin 5-HT 2A Receptor Ligands. Journal of Heterocyclic Chemistry, 46(November), 1259–1265. https://doi.org/10.1002/jhetspa
dc.relation.referencesKnechel, N. A. (2009). Tuberculosis: Pathophysiology, clinical features, and diagnosis. Critical Care Nurse, 29(2), 34–43. https://doi.org/10.4037/ccn2009968spa
dc.relation.referencesKontogiorgis, C. A., & Hadjipavlou, D. (2004). Current trends in quantitative structure activity relationships on fxa inhibitors: Evaluation and comparative analysis. In Medicinal Research Reviews (Vol. 24, pp. 687–747). https://doi.org/10.1002/med.20006spa
dc.relation.referencesKumar, A., Chaturvedi, V., Bhatnagar, S., Sinha, S., & Siddiqi, M. I. (2009). Knowledge based identification of potent antitubercular compounds using structure based virtual screening and structure interaction fingerprints. Journal of Chemical Information and Modeling, 49(1), 35–42. https://doi.org/Doi 10.1021/Ci8003607spa
dc.relation.referencesJossefa, C. (2019). Infecciones. MSD Salud. https://www.msdsalud.es/cuidar-en/infecciones/infecciones-bacterianas/se-transmiten-infecciones-bacterianas.htmlspa
dc.relation.referencesLombardino, J. G., & Lowe, J. (2004). The role of the medicinal chemist drug discovery - then and now. 3(October). https://doi.org/10.1038/nrd1523spa
dc.relation.referencesLópez, F., Medina, J. L., & Castillo, R. (2018). Diseño de fármacos asistido por computadora. Educación Química, 17(4), 452. https://doi.org/10.22201/fq.18708404e.2006.4.66027spa
dc.relation.referencesMateo, A. J., García, R. S., Sarmiento, A. M., Guidet, L. G., Gálvez, J., & García-Domenech, R. (2016). Application of molecular topology for predicting the leishmanicidal activity of a group of compounds derived from pyrrolo [1,2-α] quinoxaline. Anales de La Real Academia Nacional de Farmacia, 82(3), 317–323.spa
dc.relation.referencesMdluli, K., Kaneko, T., & Upton, A. (2015). The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets. Cold Spring Harb Perspect Med, 5(6), 1–24. https://doi.org/10.1007/978-3-642-27769-6_4970-1spa
dc.relation.referencesMedina, J. L. (2007). Aplicaciones exitosas de diseño de fármacos utilizando métodos computacionales. In Comunicaciones libres (pp. 1–8). Ciencia.spa
dc.relation.referencesMondal, S., Upamanyu, N., & Sen, D. (2013). Hybrid Computational Simulation and Modeling Assisted Structural Analysis of Anti-tubercular Molecules. Procedia Technology, 10, 53–61. https://doi.org/10.1016/j.protcy.2013.12.336spa
dc.relation.referencesMorris, G. M., Huey, R., Lindstrom, W., Sanner, M. P., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256spa
dc.relation.referencesMurcia, G. D. (2009). Microbiologia para enfermeros (U. N. de Colombia (ed.); primera).spa
dc.relation.referencesMurima, P., de Sessions, P. F., Lim, V., Naim, A. N. M., Bifani, P., Boshoff, H. I. M., Sambandamurthy, V. K., Dick, T., Hibberd, M. L., Schreiber, M., & Rao, S. P. S. (2013). Exploring the Mode of Action of Bioactive Compounds by Microfluidic Transcriptional Profiling in Mycobacteria. PLoS ONE, 8(7), 1–11. https://doi.org/10.1371/journal.pone.0069191spa
dc.relation.referencesNarwal, S., Kumar, S., & Verma, P. K. (2016). Synthesis and therapeutic potential of quinoline derivatives. Res Chem Intermed, 43, 1–34.spa
dc.relation.referencesNavarro, C. A. (2015). Estudio de disolventes ambientalmente amigables para la síntesis de 1,8-dioxo-octahidroxantenos y decahidroacridin-1,8-dionas [Universidad Nacional de Colombia]. http://www.bdigital.unal.edu.co/52085/spa
dc.relation.referencesNCBI. (2019). National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/mesh/68007239spa
dc.relation.referencesNiu, M.-M., Qin, J.-Y., Tian, C.-P., Yan, X.-F., Dong, F.-G., Cheng, Z.-Q., Fida, G., Yang, M., Chen, H., & Gu, Y.-Q. (2014). Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking. Acta Pharmacologica Sinica, 967–979. https://doi.org/10.1038/aps.2014.34spa
dc.relation.referencesNovoa, L., & Soto, C. Y. (2014). Mycobacterium tuberculosis p-type atpases: Possible targets for drug or vaccine development. BioMed Research International, 2014(January 2015). https://doi.org/10.1155/2014/296986spa
dc.relation.referencesNovoa, L., León, A., Patiño, M., Cuesta, J., Salazar, L. mary, Landsman, D., Mariño, L., & Soto, C. (2012). In silico identification and characterization of the ion transport specificity for P-type ATPases in the Mycobacterium tuberculosis complex. https://doi.org/10.1186/1472-6807-12-25spa
dc.relation.referencesNunes, C., Booty, M. G., Carpenter, S. M., Jayaraman, P., Rothchild, A. C., & Behar, S. M. (2014). In search of a new paradigm for protective immunity to TB. Nature Reviews Microbiology, 12(4), 289–299. https://doi.org/10.1038/nrmicro3230spa
dc.relation.referencesOsborne, R. (2013). First novel anti-tuberculosis drug in 40 years. Nature Biotechnology, 31(2), 89–91. https://doi.org/10.1038/nbt0213-89spa
dc.relation.referencesPaz, R. (2010). Utilización de solventes eutécticos como medio de miscibilidad de compuestos bioactivos y polisacáridos. 65. https://ciad.repositorioinstitucional.mx/jspui/handle/1006/376spa
dc.relation.referencesPérez, R. M. (1998). Resistencia bacteriana a antimicrobianos: su importancia en la toma de decisiones en la práctica diaria. Información Terapéutica Del Sistema Nacional de Salud, 57–67. http://www.mscbs.gob.es/gl/biblioPublic/publicaciones/docs/bacterias.pdfspa
dc.relation.referencesPerkinElmer. (2011). ChemDraw Professional. https://perkinelmerinformatics.com/products/research/chemdraw/spa
dc.relation.referencesPerri, M., Aiello, F., Cione, E., Carullo, G., Amendola, L., Mazzotta, S., & Caroleo, M. C. (2019). Investigation of TNBC in vitro Antiproliferative Effects of Versatile Pirrolo[1,2-a]quinoxaline Compounds. Frontiers in Molecular Biosciences, 6(March), 1–5. https://doi.org/10.3389/fmolb.2019.00012spa
dc.relation.referencesPrasad, B., Kumar, K. S., Babu, P. V., Anusha, K., Rambabu, D., Kandale, A., Vanaja, G. R., Kalle, A. M., & Pal, M. (2012). AlCl 3 induced C – N bond formation followed by Pd / C – Cu mediated coupling – cyclization strategy : synthesis of pyrrolo [ 2 , 3- b ] quinoxalines as anticancer agents. Tetrahedron Letters, 53(45), 6059–6066. https://doi.org/10.1016/j.tetlet.2012.08.119spa
dc.relation.referencesQuiñones D., (2017). Resistencia antimicrobiana: evolución y perspectivas actuales ante el enfoque "Una salud" Revista Cubana de Medicina Tropical, 69(3), 1–17. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0375-07602017000300009&lng=es&nrm=iso&tlng=esspa
dc.relation.referencesRamos, P. M., & Gil, J. (2017). Biorrefinerías basadas en explotaciones agropecuarias y forestales.Universidad de Zaragoza, November, 191.spa
dc.relation.referencesRub, C., & Konig, B. (2012). Low melting mixtures in organic synthesis – an alternative to ionic liquids? Green Chemistry, 207890, 14. https://doi.org/10.1039/b000000xspa
dc.relation.referencesSaffioti, N. A., de Sautu, M., Ferreira-Gomes, M. S., Rossi, R. C., Berlin, J., Rossi, J. P. F. C., & Mangialavori, I. C. (2019). E2P-like states of plasma membrane Ca2+‑ATPase characterization of vanadate and fluoride-stabilized phosphoenzyme analogues. Biochimica et Biophysica Acta - Biomembranes, 1861(2), 366–379. https://doi.org/10.1016/j.bbamem.2018.11.001spa
dc.relation.referencesSánchez, L., & González, D. (2017). Topología y función de las subunidades intrínsecas de la membrana de las F1F0-ATP sintasa mitocondriales. TIP Revista Especializada En Ciencias Químico-Biológicas, 20(2), 29–47. https://doi.org/10.1016/j.recqb.2017.04.004spa
dc.relation.referencesSantivañez, M., Moreno, E., Monge, A., & Pérez, S. (2013). Quinoxalinas como potenciales agentes antimycobacterium tuberculosis: una revisión. In Rev Soc Quím Perú (Vol. 79, Issue 3). http://www.scielo.org.pe/pdf/rsqp/v79n3/a10v79n3.pdfspa
dc.relation.referencesSantos, P. (2010). Sistema de transporte ATPasa en vesículas de membranas de Mycobacterium tuberculosis involucrado en la regulación de la concentración de protones: posible blanco terapéutico de la acción de péptidos antimicrobianos [Universidad Nacional de Colombia]. http://www.bdigital.unal.edu.co/3005/1/188110.2010.pdfspa
dc.relation.referencesSantos, P. (2020). ATPasas tipo P de Mycobacterium tuberculosis como dianas para el diseño racional de compuestos antituberculosos [Universidad Nacional de Colombia]. https://repositorio.unal.edu.co/handle/unal/77933spa
dc.relation.referencesSantos, P., Lopez, F., Ramírez, D., Caballero, J., Espinosa, M., Hernández-pando, R., & Soto, C. Y. (2019). Identification of Mycobacterium tuberculosis CtpF as a target for designing new antituberculous compounds. Bioorganic and Medicinal Chemistry, 115256. https://doi.org/10.1016/j.bmc.2019.115256spa
dc.relation.referencesSchrödinger LLC. (2021). Maestro. Schrödinger.spa
dc.relation.referencesSchrödinger, L. (2010). The PyMOL Molecular Graphics System, Version 1.7.4.spa
dc.relation.referencesSeddon, G., Lounnas, V., Mcguire, R., Bywater, R. P., Oliveira, L., & Vriend, G. (2012). Drug design for ever , from hype to hope. 137–150. https://doi.org/10.1007/s10822-011-9519-9spa
dc.relation.referencesShalini, P. (2016). Desarrollo de fármacos. Manual MSD. https://www.msdmanuals.com/es-co/professional/fármacología-clínica/conceptos-fármacoterapéuticos/desarrollo-de-fármacosspa
dc.relation.referencesSheen, P., Ferrer, P., Gilman, R. H., López-Llano, J., Fuentes, P., Valencia, E., & Zimic, M. J. (2009). Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland), 89(2), 109–13spa
dc.relation.referencesSheldon, R. A. (2005). Green solvents for sustainable organic synthesis: State of the art. Green Chemistry, 7(5), 267–278. https://doi.org/10.1039/b418069kspa
dc.relation.referencesSilverstein, R., Webster, F., & Kiemle, D. (n.d.). Spectrometric Identification of Organic Compunds 7th ed - R. Silverstein, et al., (Wiley, 2005) W (2).pdf (septima).spa
dc.relation.referencesSimithy, J., Reeve, N., Hobrath, J. V., Reynolds, R. C., & Calderón, A. I. (2014). Identification of shikimate kinase inhibitors among anti-Mycobacterium tuberculosis compounds by LC-MS. Tuberculosis, 94(2), 152–158. https://doi.org/10.1016/j.tube.2013.12.004spa
dc.relation.referencesSmith, E. L., Abbott, A. P., & Ryder, K. S. (2014). Deep Eutectic Solvents (DESs) and Their Applications. Chemical Reviews, 114(21), 11060–11082. https://doi.org/10.1021/cr300162pspa
dc.relation.referencesTrott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334spa
dc.relation.referencesVasava, M. S., Bhoi, M. N., Rathwa, S. K., Borad, M. A., Nair, S. G., & Patel, H. D. (2017). Drug development against tuberculosis: Past, present and future. Indian Journal of Tuberculosis, 64(4), 252–275. https://doi.org/10.1016/j.ijtb.2017.03.002spa
dc.relation.referencesWorld Health Organization. (2021). Global tuberculosis report 2021. file:///C:/Users/Nuestro compu/Downloads/9789240037021-eng.pdfspa
dc.relation.referencesWorley, M., & Estrada, S. (2014). Bedaquiline: A novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy, 34(11), 1187–1197. https://doi.org/10.1002/phar.1482spa
dc.relation.referencesZor, T., & Selinger, Z. (1996). Linearization of the Bradford Protein Assay Increases Its Sensitivity : Theoretical and Experimental Studies. 308(236), 302–308.spa
dc.relation.referencesZumla, A., Nahid, P., & Cole, S. T. (2013). Advances in the development of new tuberculosis drugs and treatment regimens. Nature Reviews. Drug Discovery, 12(5), 388–404. https://doi.org/10.1038/nrd4001spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/spa
dc.subject.ddc570 - Biología::572 - Bioquímicaspa
dc.subject.otherMycobacterium tuberculosis
dc.subject.proposalPyrrolo[1,2-a]quinoxalineseng
dc.subject.proposalDeep Eutectic Solventseng
dc.subject.proposalMycobacterium tuberculosiseng
dc.subject.proposalP-type ATPaseeng
dc.subject.proposalCtpF
dc.subject.proposalDockingeng
dc.subject.proposalPirrolo[1,2-a]quinoxalinaseng
dc.subject.proposalSolventes Eutécticos Profundosspa
dc.subject.proposalMycobacterium tuberculosisspa
dc.subject.proposalATPasa tipo Pspa
dc.subject.proposalAcoplamiento molecularspa
dc.titleDiseño in silico, síntesis y efecto en la actividad Ca2+ -ATPasa de CtpF de los compuestos derivados del núcleo pirrolo[1,2- a]quinoxalinas con potencial antimicobacterianospa
dc.title.translatedIn silico design, synthesis and effect on Ca2+ -ATPase activity of CtpF of pyrrolo[1,2- a]quinoxaline core-derived compounds with antimycobacterial potentialeng
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentEstudiantesspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Tesis de maestria Michael Daniela Rodriguez Afanador .pdf
Tamaño:
1.89 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Maestría en Ciencias - Bioquímica

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
3.98 KB
Formato:
Item-specific license agreed upon to submission
Descripción: